BPC-157 Mild GI Symptoms That Won't Go Away: Causes, Duration, and What to Do

What BPC-157 is

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice [1]. It is not an FDA-approved drug, and no FDA-approved product contains it [1]. In July 2026 FDA's compounding advisory committee voted in favor of adding it to the pharmacy bulks list, against FDA staff's recommendation. That vote is nonbinding advice, and BPC-157 is not on the list [1][3]. FDA noted that websites sell BPC-157 as capsules, injections and oral or nasal sprays, some labeled for research only, and that these are not approved drugs [1].

The gut effects attributed to it come from rat studies. FDA's July 2026 review said its molecular targets have not been identified and its mechanisms 'remain poorly understood' [1].

What the human reports show

FDA found no human studies of BPC-157 given by mouth, by subcutaneous injection, as a nasal spray or on the skin [1]. Small studies used other routes: knee injections for pain, bladder-wall injections in 12 women with interstitial cystitis, and an intravenous pilot in 2 adults. No adverse events were reported in them [4][5][6].

The gut-related human data come from rectal enemas. In the healthy-volunteer enema studies, which were meeting abstracts, the most frequent events were headache and flatulence [1]. A 2-week ulcerative colitis enema study (meeting abstract only) gave 53 people 80 mg daily or placebo. It reported no difference in adverse events versus placebo, and FDA said the abstract had too little detail to judge effectiveness [1].

FDA searched its adverse-event database through December 4, 2025 and found 3 reports, all for injectable BPC-157:

• injection-site redness and swelling lasting 9 days, in a patient who also used compounded thymosin;
• shortness of breath leading to an emergency room visit, with no other detail;
• widespread skin and gum darkening that recurred after re-exposure to a product containing BPC-157 and TB-500.

FDA said it cannot tell whether BPC-157 caused any of them [1].

What is known about absorption

There are no human pharmacokinetic data for BPC-157 given orally, subcutaneously, nasally or on the skin [1]. After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, and FDA judged it appears not to be absorbed systemically by that route [1].

The safety picture

FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. FDA's compounding page, where BPC-157 now sits in a 'nominated but withdrawn' table, still carries its stated concern that compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' and may have problems with peptide-related impurities and characterization of the active ingredient [7].

A 2026 systematic review of BPC-157 in orthopaedic and regenerative use found 3 studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low. The reviewers concluded it should not be used clinically outside ethically approved, regulated, high-quality trials [2].